MEDSCI Reports Mid-Year Net Profit of 10.638 Million Yuan, Down 19.7% Year-on-Year
Stock News
Aug 31
MEDSCI (02415) has unveiled its interim results for the 2026 fiscal year, showcasing a period marked by notable financial shifts.
During the reporting period, the group generated total revenue of 117 million yuan (RMB), reflecting a year-on-year decline of 6.2%. Meanwhile, net profit reached 10.638 million yuan, representing a decrease of 19.7% compared to the prior year. Basic earnings per share stood at 1.94 fen.
The company attributed the revenue dip to the growing prevalence of AI technology, which has reduced the demand for certain simple, language-based clinical research services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.